3-year study of @entity8124 therapy in XXXX : effects of early and continuous therapy.

@entity1 @entity8124 @entity146 @entity195
Delays in the diagnosis of @entity195 , and, therefore, delays in treatment, may have a detrimental effect on a @entity1 's long-term well-being. This study assessed the effects of postponing @entity8124 treatment for 1 year by comparing @entity1 treated continuously for 3 years with those who received placebo for 1 year followed by open-label @entity8124 for 2 years. @entity1 (n = 286) with possible or probable @entity195 (according to DSM-IV, NINCDS-ADRDA, and Mini-Mental State Examination criteria; see text) were randomized to receive @entity8124 (5 mg/day for 4 weeks, 10 mg/day thereafter) or placebo (delayed-start group) for 1 year. Of the 192 completers, 157 began a 2-year, open-label phase of @entity8124 treatment. Outcome measures were the Gottfries-Br  ne-Steen scale, the Mini-Mental State Examination, the Global Deterioration Scale, the Progressive Deterioration Scale, the @entity146 Inventory, and safety (adverse events). Mixed regression analysis was used to compare changes between the groups over 3 years on the efficacy measures. There was a trend for @entity1 receiving continuous therapy to have less global deterioration (Gottfries-Br  ne-Steen scale) than those who had delayed treatment (p = 0.056). Small but statistically significant differences between the groups were observed for the secondary measures of cognitive function (Mini-Mental State Examination; p = 0.004) and cognitive and functional abilities (Global Deterioration Scale; p = 0.0231) in favor of continuous @entity8124 therapy. Over 90% of the @entity1 in both cohorts experienced one treatment-emergent adverse event; most were considered mild or moderate. In conclusion, @entity1 in whom the start of treatment is delayed may demonstrate slightly reduced benefits as compared with those seen in @entity1 starting @entity8124 therapy early in the course of @entity195 . These data support the long-term efficacy and safety of @entity8124 .
